Hong Kong flagged a banned dye in a Korean face cream on 24 July. By 6 September, Singapore's own batch tests showed the contamination sat with one unauthorized reseller, not the brand's official supply chain

What happened, batch by batch

Medicube, a South Korean skincare brand owned by APR, sells its PDRN Pink Collagen Capsule Cream across Asia through a mix of official subsidiaries, licensed wholesalers and independent retailers that import the product outside the brand's own contracts. That mix is where this case starts. On 24 July 2026, Hong Kong's Customs and Excise Department issued a public alert after its Government Laboratory tested a sample of the cream bought from a local shop and found Sudan Red, citing two separate violations of the Consumer Goods Safety Ordinance (CGSO): the prohibited dye itself, and a missing Chinese-language warning statement on packaging that carried only English and Korean text, a requirement under the Consumer Goods Safety Regulation. A week later, on 31 July 2026, Singapore's HSA opened its own investigation and directed three companies marketing the identical product in Singapore, APR SG Pte Ltd (Medicube's own Singapore subsidiary), Rirora International Pte Ltd (a wholesaler) and Venus Beauty Pte Ltd (a retailer that, according to reporting on the case, parallel-imports 14 different Medicube products), to suspend sales while it tested samples submitted by each of them separately. On 26 August 2026, HSA reported that two specific batches submitted by Venus Beauty had tested positive for minute amounts of Sudan IV and instructed their recall; the samples submitted by APR SG and Rirora tested clear. APR's own account, reported on 6 September 2026 when HSA lifted the suspension on APR SG's batches, the last of the three to be cleared, adds the detail that separates this from an ordinary recall: the company said the batch numbers HSA tested from Venus Beauty have no record of ever having been exported to Singapore through its own official channel.

The numbers behind the two recalls

One number shows how many supply chains a single product listing can actually hide. One shows how long it took two governments, working independently, to sort out which one was the problem. The third is the standing penalty a seller faces the moment its own batch tests positive.

The real subject: a product name is not a compliance record

Most coverage of this case, in Hong Kong and in Singapore, described it the way a shopper would experience it: a specific cream, a banned dye, a recall. That framing is accurate, but it skips the step that actually resolved the case. HSA did not treat the fact that a Medicube PDRN Pink Collagen Capsule Cream was on sale in Singapore as one product with one compliance status. It treated the listing as three separate supply streams, one per company selling it, suspended each independently on 31 July, and tested each company's own submitted stock rather than assuming a single lab result applied to every unit carrying that name on a shelf. That separation is what surfaced the actual distinction: two of the three streams traced back to stock the companies could account for, and both came back clear. The third did not, and APR says it cannot even confirm those specific units passed through its own supply chain, because the batch numbers HSA tested carry no export record on its side. A shopper looking at a shelf, or at a marketplace listing, cannot see that difference. The product name, the packaging and the price point look identical whether a unit came through a channel with a documented export trail or through a reseller sourcing stock outside the brand's own contracts. Only batch-level testing, matched against each seller's own records, showed which units were the actual risk, and Hong Kong's separate labeling finding, on the very same product name, is a reminder that even that is only one axis of compliance: a unit can carry a prohibited ingredient, a missing local-language warning, or both, depending on which market and which channel it moved through.

Why it matters for brands

The direct exposure sits with any beauty brand selling into Hong Kong and Singapore through more than one channel at once, official subsidiary, licensed wholesaler and unauthorized reseller together, since this case shows a regulator will not wait for a brand to sort out which seller's stock is genuine before acting: HSA suspended all three companies on the same day and left it to batch-level testing, not brand identity, to clear two of them six weeks later. That puts a concrete compliance burden on any brand operating this way: the ability to say, within days of a suspension notice, whether a specific batch number was ever exported through its own official channel, the way APR could when it disputed the Venus Beauty samples. A brand without that batch-to-export mapping on hand cannot make that argument at all, and has no way to separate its own liability from a parallel importer's. Second, this is not only a Singapore or Hong Kong problem: Sudan Red dyes are prohibited cosmetic ingredients well beyond these two markets, so any brand using the same colouring agent or raw-material supplier across other export markets should treat two independent positive findings, six weeks apart, from two different regulators testing two different retail samples, as reason to check its own colourant source directly rather than wait for a third market to flag it. Third, Hong Kong's separate finding, a missing Chinese-language warning on the same packaging, is a reminder that a prohibited-ingredient check and a local-language labeling check are two different compliance requirements under two different provisions: passing one does not imply passing the other, and a brand's review process needs to run both, market by market, rather than treat a single ingredient recall as the whole picture.

Two ways to read the Medicube case

Frequently asked questions